Trials / Completed
CompletedNCT02480751
TRK-100STP PhaseII Clinical Study -Chronic Renal Failure (Primary Glomerular Disease/Nephrosclerosis)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 113 (actual)
- Sponsor
- Toray Industries, Inc · Industry
- Sex
- All
- Age
- 20 Years – 79 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine the recommended dose of the sustained-release form of BPS (TRK-100STP low dose or high dose) in Japanese patients with CRF (Primary glomerular disease/nephrosclerosis).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Beraprost | |
| DRUG | Placebo |
Timeline
- Start date
- 2005-10-01
- Primary completion
- 2008-05-01
- First posted
- 2015-06-24
- Last updated
- 2015-06-29
Source: ClinicalTrials.gov record NCT02480751. Inclusion in this directory is not an endorsement.